Authorizations for provider-administered medications
At Moda Health, we’re committed to supporting your practice and the care you provide your patients. Follow this guidance for submitting prior authorizations, which includes additional details about medical pharmacy programs.
Infused and injectable medication program
Moda Health partners with Prime Therapeutics Management to assist you in medical pharmacy management through the provider administered infused and injectable medication program. Moda Health is committed to providing our members with access to high-quality healthcare. With this commitment in mind and to ensure quality care and affordability for our members, we offer several programs centered around provider administered medications.
Important Note: Quantities billed for discarded amounts (modifier JW) count toward the total preauthorized quantity. Provider offices should include anticipated discard amounts in the preauthorization request to ensure coverage for both the prescribed dose and any waste from single-use vials.
Injectable medications covered under the medical benefit
Prime Therapeutics Management or Moda Health will review your prior authorization requests for select specialty injectable/infused medications that are given in an outpatient facility, a patient’s home, or a physician’s office.
Texas fully insured individuals
Prior authorization is not required; however, post-service claims edits will apply. Moda Health applies post-service, pre-payment claims edits to diagnosis criteria and criteria for maximum billing units for the medications found here. Please note that only diagnosis code criteria and maximum billing units will apply and claims may be denied when used for unsupported indications or at a dose/frequency inconsistent with how the medication is intended to be used. Site of Care requirements (described below) do not apply.
Texas equal funding groups
All prior authorization requests for equal funding groups will go through Prime Therapeutics Management directly. Post service claim edits program (PSCE) and Site of Care program requirements (described below) will apply.
Texas fully insured groups
All prior authorization requests for fully insured groups will go through Moda Health directly. Post service claim edits program (PSCE) and Site of Care program requirements (described below) do not apply.
Infused and injectable medication utilization management programs
Post Service Claim Edits Program (PSCE)
In partnership with Prime Therapeutics Management, Moda Health has a claim check program for injectable and/or infusion medications. The claim check program monitors and promotes appropriate use, safety, and cost effectiveness of medications prescribed to our members. We do this by reviewing claims post-service, but pre-payment for appropriate frequency, correct units, and eligible diagnosis codes.
This program only applies to Texas Equal Funding Groups at this time.
- Azedra® (iobenguane I-131)
- Bortezomib
- Cinvanti® (aprepitant)
- Fosaprepitant: Emend®; Fosaprepitant; Focinvez
- Fulvestrant: Faslodex®; Fulvestrant Ψ
- Gemcitabine: Gemzar®; Gemcitabine
- Hicon® (Sodium Iodide I - 131)
- Leuprolide Suspension: Lupron Depot®, Lupron Depot-Ped®, Eligard®, Fensolvi®, Camcevi™, Lutrate Depot™, Leuprolide Acetate Depot
- Lutathera® (lutetium Lu 177 dotatate)
- Metastron™ (Strontium-89 Chloride)
- Palonosetron: Aloxi®; Posfrea™
- Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)
- Quadramet® (Samarium Sm 153 Lexidronam)
- Scenesse® (afamelanotide)
- Tevimbra™ (tislelizumab-jsgr)
- Trelstar® (triptorelin)
- Xofigo® (radium Ra 223 dichloride)
- Zevalin® (ibritumomab tiuxetan)
- Zoladex® (goserelin acetate)
Site of Care Specialty Infusion Program
Through the current prior authorization program administered by Prime Therapeutics Management, infusion requests for a hospital outpatient setting for the medications listed under “Injectable Medication Criteria Policies” will be redirected to a preferred site of service, which will be either preferred home infusion providers or a professional office setting. Infusions for these medications will not be covered when administered in a hospital outpatient infusion center.
The medications included in the Site of Care program already require prior authorization through Prime Therapeutics Management. The Site of Care program requirements will be administered as part of the existing prior authorization program. As a reminder, Moda will deny services as provider responsibility when prior authorization is not obtained for any medications that require prior authorization.
This program only applies to Texas Equal Funding Groups. Texas Individual and Texas Large Group members are not subject to this program.
Injectable Medication Criteria Policies
Most infused or injectable medications are reviewed by Prime Therapeutics Management, but some are reviewed by Moda Health. Please see the bottom of the Injectable Medication Prior Authorization List to find out which medications should be submitted directly to Moda Health.
- Abecma® (idecabtagene vicleucel)
- Adcetris® (brentuximab vedotin)
- Adakveo® (crizanlizumab-tmca)
- Adstiladrin® (nadofaragene firadenovec-vncg)
- Aduhelm
- Adzynma® (ADAMTS13, recombinant-krhn)
- Aflibercept: Ahzantive™; Enzeevu™; Eydenzelt®; Eylea®; Eylea® HD; Opuviz™; Pavblu™; Yesafili™
- Akynzeo® (fosnetupitant/palonosetron)
- Aldurazyme® (laronidase)
- Alhemo® (concinzumab)
- Aloxi® (palonosetron)
- Alpha-1-Proteinase Inhibitors: Aralast NP®; Glassia®; Prolastin®-C; Zemaira®
- Amondys 45 (casimersen)
- Amtagvi® (lifileucel)
- Amvuttra (vutrisiran)
- Anktiva® (nogapendekin alfa inbakicept-pmln)
- Aphexda™ (motixafortide)
- Aranesp® (darbepoetin alfa)
- Asparlas® (calaspargase pegol-mknl)
- Arzerra® (ofatumumab)
- Aucatzyl® (Obecabtagene Autoleucel - Obe-cel)
- Bavencio® (avelumab)
- Beleodaq® (belinostat)
- Bendamustine: Treanda®; Bendeka®; Belrapzo®; Vivimusta™; Bendamustine Ψ
- Benlysta® (belimumab)
- Beovu® (brolucizumab-dbll)
- Berinert® (C1 Esterase Inhibitor, Human)
- Besponsa® (inotuzumab ozogamicin)
- Beqvez™ (fidanacogene elaparvovec-dzkt)
- Bevacizumab: Alymsys®; Avastin®; Avzivi®; Jobevne™; Mvasi®; Vegzelma®; Zirabev®
- Bizengri® (zenocutuzumab-zbco)
- Blenrep® (belantamab mafodotin-blmf)
- Blincyto® (blinatumomab)
- Botox® (onabotulinumtoxinA)
- Breyanzi® (lisocabtagene maraleucel)
- Brineura® (cerliponase alfa)
- Briumvi™ (ublituximab-xiiy)
- Bypassing Agents: FEIBA and NovoSeven RT
- Cabazitaxel: Jevtana®; Cabazitaxel§
- Carvykti™ (ciltacabtagene autoleucel)
- Casgevy™ (exagamglogene autotemcel)
- Cerezyme® (imiglucerase)
- Cimzia® (certolizumab pegol)
- Cinqair® (reslizumab)
- Cinryze® (C1 Esterase Inhibitor, Human)
- Coagulation Factor X, human (Coagadex®)
- Coagulation Factor XIII A-Subunit, recombinant (Tretten)
- Columvi™ (glofitamab-gxbm)
- Corticotropin-ACTH: Acthar® Gel (repository corticotropin injection) Cortrophin® Gel (repository corticotropin injection)
- Cosela™ (trilaciclib)
- Cosentyx® (secukinumab)
- Crysvita® (burosumab-twza)
- Cyramza® (ramucirumab)
- Danyelza® (naxitamab-gqgk)
- Darzalex® (daratumumab)
- Darzalex Faspro® (daratumumab and hyaluronidase-fihj)
- Datroway® (datopotamab deruxtecan-dlnk)
- Daxxify® (daxibotulinumtoxinA)
- Denosumab: Prolia®; Jubbonti®; Ospomyv™; Stoboclo®; Denosumab-dssb; Conexxence®; Denosumab-bnht; Xgeva®; Wyost®; Xbryk™; Osenvelt®; Bomyntra®
- Dysport® (abobotulinumtoxinA)
- Eculicumab: Soliris®; Bkemv™; Epysqli®
- Elahere™ (mirvetuximab soravtansine-gynx)
- Elaprase® (idursulfase)
- Elelyso® (taliglucerase alfa)
- Elevidys® (delandistrogene moxeparvovec-rokl)
- Elfabrio® (pegunigalsidase alfa-iwxj)
- Elrexfio™ (elranatamab-bcmm)
- Elzonris™ (tagraxofusp-erzs)
- Empliciti® (elotuzumab)
- Emrelis™ (telisotuzumab vedotin-tllv)
- Encelto™ (revakinagene taroretcel-lwey)
- Enhertu® (fam-trastuzumab deruxtecan-nxki)
- Enjaymo™ (sutimlimab-jome)
- Entyvio® (vedolizumab)
- Epkinly™ (epcoritamab-bysp)
- Epoetin alfa: Epogen®; Procrit®; Retacrit®
- Erbitux® (cetuximab)
- Evenity® (romosozumab-aqqg)
- Evkeeza™ (evinacumab-dgnb)
- Exondys 51 (eteplirsen injection)
- Extended Half-life Factor IX Products: Alprolix, Idelvion, and Rebinyn
- Extended Half-life Factor VIII Products: Altuviiio, Adynovate, Eloctate, Esperoct and Jivi
- Fabrazyme® (agalsidase beta)
- Factor V Leiden Thrombophilia
- Factor VIII/VWF Complex: Alphanate®, Humate-P®, and Wilate®
- Factor XIII Concentrate, human (Corifact)
- Fasenra® (benralizumab)
- Feraheme® (ferumoxytol)
- Gamifant® (emapalumab-lzsg)
- Gazyva® (obinutuzumab)
- Givlaari® (givosiran)
- Halaven® (eribulin)
- Hemgenix® (etranacogene dezaparvovec-drlb)
- Hemlibra® (emicizumab-kxwh)
- Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk)
- Hyaluronic Acid Derivatives: Durolane®, Euflexxa™, Gel-One®, GelSyn-3™, GenVisc 850®, Hyalgan™, Hymovis®, Monovisc®, Orthovisc™, Supartz/Supartz FX™, Synojoynt, Synvisc™, Synvisc-One™, Triluron™, TriVisc™, VISCO-3™, & sodium hyaluronate 1%
- Hympavzi® (marstacimab-hncq)
- Imjudo® (tremelimumab-actl)
- Ilaris® (canakinumab)
- Ilumya® (tildrakizumab-asmn)
- Imaavy™ (nipocalimab-aahu)
- Imdelltra™ (tarlatamab-dlle)
- Imfinzi® (durvalumab)
- Imlygic™ (talimogene laherparepvec)
- IVIG (immune globulin IV): Asceniv™; Alyglo™; Bivigam®; Flebogamma®; Gamunex-C®; Gammagard® Liquid; Gammagard® S/D; Gammagard Liquid ERC®; Gammaked™; Gammaplex®; Octagam®; Privigen®; Panzyga®; Yimmugo®
- Implantable Shock Absorber for Knee OA Treatment
- Infliximab: Remicade®; Inflectra®; Renflexis™; Avsola®; Infliximab*
- Injectafer® (ferric carboxymaltose injection)
- Inlexzo™ (gemcitabine)
- Itvisma® (onasemnogene abeparvovec-brve)
- Ixempra® (ixabepilone)
- Izervay™ (avacincaptad pegol)
- Jelmyto™ (mitomycin)
- Jemperli® (dostarlimab-gxly)
- Kadcyla® (ado-trastuzumab emtansine)
- Kalbitor® (ecallantide)
- Kanuma® (sebelipase alfa)
- Keytruda® (pembrolizumab)
- Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph)
- Kresladi™ (marnetegragene autotemcel)
- Krystexxa® (pegloticase)
- Kymriah® (tisagenlecleucel)
- Kyprolis® (carfilzomib)
- Kyxata™ (carboplatin)
- Lamzede® (velmanase alfa-tycv)
- Lanreotide: Somatuline® Depot; Lanreotide
- Lemtrada® (alemtuzumab)
- Lenmeldy™ (atidarsagene autotemcel)
- Leqembi® (lecanemab-irmb)
- Leqvio® (inclisiran)
- Leukine® (sargramostim)
- Levoleucovorin: Fusilev®; Khapzory™
- Libtayo® (cemiplimab-rwlc)
- Long-Acting Granulocyte Colony Stimulating Factors (LA-GCSF): Fulphila®; Fylnetra®; Neulasta®; Nyvepria™; Pegfilgrastimfpgk; Rolvedon®; Ryzneuta®; Stimufend®; Udenyca®; Ziextenzo®
- Loqtorzi™ (toripalimab-tpzi)
- Lumizyme® (alglucosidase alfa)
- Lumoxiti™ (moxetumomab pasudotox-tdfk)
- Lunsumio™ (mosunetuzumab-axgb)
- Lunsumio Velo™ (mosunetuzumab-axgb)
- Luxturna (voretigene neparvovec-rzyl)
- Lyfgenia® (lovotibeglogene autotemcel)
- Lymphir™ (denileukin diftitox-cxdl)
- Lynozyfic™ (linvoseltamab-gcpt)
- Margenza™ (margetuximab-cmkb)
- Marqibo® (vincristine sulfate liposomal)
- Mepsevii® (vestronidase alfa-vjbk)
- Monjuvi® (tafasitamab-cxix)
- Monoferric™ (ferric derisomaltose)
- Mylotarg™ (gemtuzumab ozogamicin)
- Myobloc® (rimabotulinumtoxinB)
- Naglazyme® (galsulfase)
- Natalizumab: (Tysabri®; Tyruko®)
- Nexviazyme™ (avalglucosidase alfa-ngpt)
- Niktimvo™ (axatilimab-csfr)
- Nplate® (romiplostim)
- Nucala® (mepolizumab)
- Nulibry™ (fosdenopterin)
- Ocrevus® (ocrelizumab)
- Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq)
- Omisirge® (omidubicel-onlv)
- Omvoh™ (mirikizumab-mrkz)
- Onivyde® (irinotecan liposome injection)
- Onpattro (patisiran lipid complex)
- Opdivo® (nivolumab)
- Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy)
- Opdualag™ (nivolumab/relatlimab-rmbw)
- Orencia® (abatacept)
- Oxlumo® (lumasiran)
- Paclitaxel Albumin-Bound: Abraxane®; Paclitaxel Albumin-Bound
- Padcev® (enfortumab vedotin-ejfv)
- Papzimeos™ (zopapogene imadenovec-drba)
- Pedmark® (sodium thiosulfate)
- Pemetrexed: Alimta®; Pemfexy™; Pemrydi RTU™; Axtle™; Pemetrexed Ψ
- Penpulimab-KCQX (penpulimab-kcqx)
- Perjeta® (pertuzumab)
- Phesgo™ (pertuzumab, trastuzumab and hyaluronidase-zzxf)
- Piasky™ (crovalimab-akkz)
- Polivy® (polatuzumab vedotin-piiq)
- Pombiliti™ (cipaglucosidase alfa-atga)
- Portrazza™ (necitumumab)
- Poteligeo® (mogamulizumab-kpkc)
- Proleukin® (aldesleukin, IL-2)
- Provenge® (sipuleucel-T)
- Qalsody™ (tofersen)
- Qfitlia™ (fitusiran)
- Radicava® (edaravone)
- Ranibizumab: Lucentis®; Byooviz™; Cimerli™
- Reblozyl® (luspatercept-aamt)
- Recombinant antihemophilic factor (Obizur®)
- Revcovi® (elapegademase-lvlr)
- Rituxan Hycela® (rituximab and hyaluronidase human)
- Rituximab: Rituxan®, Truxima®, Ruxience™, Riabni™
- Rivfloza™ (nedosiran)
- Roctavian® (valoctocogene roxaparvovec-rvox)
- Ruconest® (C1 Esterase Inhibitor [recombinant])
- Rybrevant™ (amivantamab-vmjw)
- Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj)
- Rylaze® (asparaginase Erwinia chrysanthemi (recombinant)-rywn)
- Ryoncil® (remestemcel-L-rknd)
- Rystiggo® (rozanolixizumab-noli)
- Rytelo® (imetelstat)
- Ryzneuta® (efbemalenograstim alfa-vuxw)
- Sandostatin® LAR (octreotide suspension)
- Saphnelo® (anifrolumab-fnia)
- Sarclisa® (isatuximab-irfc)
- SCIG (immune globulin SQ): Hizentra®, Gammagard Liquid®, Gamunex®-C, Gammaked™, HyQvia®, Cuvitru®, Cutaquig®, Xembify®
- Short-Acting Granulocyte Colony Stimulating Factors (SA-gCSF): Filgrastim (Neupogen®); Filgrastim-aafi (Nivestym™); Filgrastim-sndz (Zarxio®); Filgrastim-ayow (Releuko®); Tbo-Filgrastim (Granix®); Filgrastim-txid (Nypozi™)
- Signifor® LAR (pasireotide)
- Simponi ARIA® (golimumab)
- Skyrizi® (risankizumab-rzaa)
- Skysona® (elivaldogene autotemcel)
- Spevigo® (spesolimab)
- Spinal Cord Stimulators
- Spinraza® (nusinersen)
- Spravato™ (esketamine)
- Standard Half-life Factor VIII Products: Advate, Afstyla, Hemofil M, Koate DVI, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, and Xyntha
- Standard Half-life Factor IX Products: AlphaNine SD, BeneFIX, Ixinity, MonoNine, Profilnine SD, and Rixubis
- Sustol® (granisetron extended-release) (Subcutaneous) Document
- Susvimo™ (ranibizumab)
- Syfovre™ (pegcetacoplan)
- Sylvant® (siltuximab)
- Talvey™ (talquetamab-tgvs)
- Tecartus® (brexucabtagene autoleucel)
- Tecelra® (afamitresgene autoleucel)
- Tecentriq® (atezolizumab)
- Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs)
- Tecvayli™ (teclistamab-cqyv)
- Tepezza® (teprotumumab-trbw)
- Tevimbra™ (tislelizumab-jsgr)
- Tezspire® (tezepelumab-ekko)
- Tivdak® (tisotumab vedotin-tftv)
- Tocilizumab: Actemra®; Tofidence™; Tyenne®; Avtozma®; Tocilizumab-anoh§; Tocilizumab-aazg§
- Trastuzumab: Herceptin®; Ogivri®; Kanjinti®; Trazimera™; Herzuma®; Ontruzant®
- Tremfya® (guselkumab)
- Trogarzo™ (ibalizumab-uiyk)
- Trodelvy® (sacituzumab govitecan-hziy)
- Tzield™ (teplizumab-mzwv)
- Ultomiris® (ravulizumab-cwvz)
- Unloxcyt® (cosibelimab-ipdl)
- Uplizna® (inebilizumab-cdon)
- Ustekinumab: Stelara®; Wezlana™; Selarsdi™; Pyzchiva®; Otulfi™; Imuldosa®; Yesintek™; Steqeyma®; Starjemza™; Ustekinumab-aekn§; Ustekinumab-ttwe§; Ustekinumab-aauz§; Ustekinumab-stba§; Ustekinumab§
- Vabysmo™ (faricimab-svoa)
- Vectibix® (panitumumab)
- Veopoz® (pozelimab-bbfg)
- Velcade® (bortezomib)
- Viltepso (viltolarsen)
- Vyepti® (eptinezumab-jjmr)
- Vimizim (elosulfase alfa)
- Von Willebrand factor (Vonvendi®)
- VPRIV® (velaglucerase alfa)
- Vyjuvek™ (beremagene geperpavec-svdt)
- Vyloy® (zolbetuximab-clzb)
- Vyondys 53 (golodirsen)
- Vyvgart® (efgartigimod alfa-fcab)
- Vyvgart® Hytrulo (efgartigimod alfa-fcab and hyaluronidase-qvfc)
- Vyxeos® (daunorubicin and cytarabine) liposome
- Winrevair™ (sotatercept-csrk)
- Xenpozyme™ (olipudase alfa)
- Xeomin® (incobotulinumtoxinA)
- Xiaflex (collagenase)
- Xolair® (omalizumab)
- Yartemlea® (narsoplimab-wuug)
- Yervoy® (ipilimumab)
- Yescarta® (axicabtagene ciloleucel)
- Yondelis® (trabectedin)
- Ziihera® (zanidatamab-hrii)
- Zilretta® (triamcinolone acetonide ER)
- Zaltrap® (ziv-aflibercept)
- Zolgensma® (onasemnogene abeparvovec-xioi)
- Zepzelca® (lurbinectedin)
- Zevaskyn™ (prademagene zamikeracel)
- Zulresso (brexanalone)
- Zusduri™ (mitomycin)
- Zynlonta® (loncastuximab tesirine-lpyl)
- Zynteglo® (betibeglogene autotemcel)
- Zynyz™ (retifanlimab-dlwr)
Working together to improve patient care
Making sure our members receive the best possible care at the most affordable price is why we come to work each day. But we can't do this alone. We appreciate your support in assuring Moda Health members receive high quality, affordable care and deliver results consistent with nationally recognized clinical criteria and guidelines.
To learn more about our injectable medication program, please take a look at our FAQs about our Injectable Drug Program or call our Customer Service team toll-free at 877-605-3229.
Questions?
Medical Customer Service is at 844-931-1779.
We're available 6:00 a.m. to 6:00 p.m. Monday through Friday, 9:00 a.m. to Noon Saturday, Sunday, and Holidays (Central Time).